Artesunate Vaginal Insert

About Frantz Viral Therapeutics

Frantz Viral Therapeutics is a clinical-stage biotech developing topical artesunate-based therapies for HPV-induced high-grade squamous intraepithelial lesions (HSIL), a precursor to cancer. Its core value proposition is a non-surgical, self-administered treatment that could significantly improve access and reduce morbidity, particularly in low-resource settings. The company has advanced its lead programs into Phase IIB trials for cervical and vulvar HSIL, building on positive Phase I/IIA data, and is backed by a team of renowned HPV experts. FVT aims to provide a first-in-class pharmacological option for a global patient population currently reliant on surgical procedures.

Therapeutic Areas